Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

Blood (2018) 132 (Supplement 1): 790.

https://doi.org/10.1182/blood-2018-99-116803

Published: 2018

Journal Articles

Kinetics of the Leukemic Clone in Patients with Chronic Myeloid Leukemia during Pregnancy

Ekaterina Chelysheva, MD PhD, Jane Apperley, MB ChB MD, Elisabetta Abruzzese, Dong-Wook Kim, MD PhD, Konstantin Kotlyarchuk, Oleg Shukhov, MD PhD, Anna G Turkina, Prof., MD

Blood (2018) 132 (Supplement 1): 4254.

https://doi.org/10.1182/blood-2018-99-115984

Published: 2018

Journal Articles

Chronic Myeloid Leukemia Diagnosed during Pregnancy: Therapy, Outcomes and Follow-up

Ekaterina Chelysheva, MD PhD, Elisabetta Abruzzese, Delphine Rea, MD, Dong-Wook Kim, MD PhD, Khamida Kazakbaeva, MD, Sukhrob Saliev, Konstantin Kotlyarchuk, Evgenia Polushkina, Roman Shmakov, MD PhD, Julia Chabaeva, Sergei M. Kulikov, PhD, Anna G Turkina, Prof., MD

Blood (2018) 132 (Supplement 1): 4255.

https://doi.org/10.1182/blood-2018-99-115983

Published: 2018

Journal Articles

Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Interim Results of Russian Prospective Multicenter Trial RU-SKI

Anna Petrova, MD, Ekaterina Chelysheva, MD PhD, Oleg Shukhov, MD PhD, Anastasiya Bykova, MD, Galina Gusarova, MD PhD, Irina Nemchenko, MD PhD, Nikolay Tsyba, MD PhD, Anna G Turkina, Prof., MD, Tatiana Nikitina, PhD, Natalia Porfirieva, Anna Zinkovskaya, Tatiana Ionova, DSc

Blood (2018) 132 (Supplement 1): 3023.

https://doi.org/10.1182/blood-2018-99-113360

Published: 2018

Journal Articles

Prognostic Model of Successful Tyrosine Kinase Inhibitors Discontinuation Based on the Russian RU-SKI Multicenter Prospective Study

Oleg Shukhov, MD PhD, Ekaterina Chelysheva, MD PhD, Anna Petrova, MD, Anastasiya Bykova, MD, Irina Nemchenko, MD PhD, Galina Gusarova, MD PhD, Eduard Gemdzhian, Anna G Turkina, Prof., MD

Blood (2018) 132 (Supplement 1): 1740.

https://doi.org/10.1182/blood-2018-99-116321

Published: 2018

Journal Articles

Analysis of the Effectiveness of Maintenance Therapy By Imatinib in Patients with Pdgfra -Positive Neoplasm

Irina Nemchenko, MD PhD, Nikolay Tsyba, MD PhD, Ekaterina Chelysheva, MD PhD, Oleg Shukhov, MD PhD, Anna G Turkina, Prof., MD

Blood (2018) 132 (Supplement 1): 1755.

https://doi.org/10.1182/blood-2018-99-116262

Published: 2018

Journal Articles

Long-Term Results and Characteristics of Pleural Effusion in Late Chronic Phase Chronic Myeloid Leukemia Patients at Dasatinib Therapy after Imatinib Failure

Galina Gusarova, MD PhD, Anastasia Bykova, MD, Alexandra Vorontsova, MD PhD, Sergey Kuznetsov, MD, Oleg Shukhov, MD, Ekaterina Chelysheva, MD PhD, Olga Lazareva, MD PhD, Svetlana Goryacheva, MD PhD, Tatyana Ivanova, MD PhD, Anna G. Turkina, MD PhD

Blood (2015) 126 (23): 5141.

https://doi.org/10.1182/blood.V126.23.5141.5141

Published: 2015

Journal Articles

Alterations in the Physiology of Multipotent Mesenchymal Stromal Cells from the Bone Marrow of Patients with Leukemia

Tamara Sorokina, MD, Irina Shipounova, PhD, Alexey Bigildeev, PhD, Nataliya Petinati, PhD, Nina I. Drize, PhD, Anna Turkina, Prof., MD, Ekaterina Chelysheva, MD PhD, Oleg Shukhov, MD, Larisa A. Kuzmina, MD PhD, Elena N. Parovichnikova, MD PhD, Valeriy G Savchenko, PhD MD

Blood (2015) 126 (23): 4768.

https://doi.org/10.1182/blood.V126.23.4768.4768

Published: 2015

Journal Articles

Pharmacoeconomical Analysis of Chronic Myelogenous Leukemia Treatment Free Remission

Vasily Shuvaev, MD, Kudrat Abdulkadyrov, MD PhD, Anna Turkina, Prof., MD, Irina Martynkevich, MD PhD, Ekaterina Chelysheva, MD PhD, Mikhail Fominykh, MD, Valentin Martchenko

Blood (2015) 126 (23): 3293.

https://doi.org/10.1182/blood.V126.23.3293.3293

Published: 2015

Journal Articles

Polymorphism of UGT1A1 and Frequency of Hyperbilirubinemia in Patients with Chronic Myeloid Leukemia Treated By Nilotinib

Anastasia Bykova, MD, Adhamjon Abdullaev, MD PhD, Galina Gusarova, MD PhD, Ekaterina Chelysheva, MD PhD, Svetlana Treglazova, MD, Svetlana Smirnova, MD, Anna G. Turkina, MD PhD

Blood (2014) 124 (21): 5538.

https://doi.org/10.1182/blood.V124.21.5538.5538

Published: 2014

NARROW

Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

Kinetics of the Leukemic Clone in Patients with Chronic Myeloid Leukemia during Pregnancy

Chronic Myeloid Leukemia Diagnosed during Pregnancy: Therapy, Outcomes and Follow-up

Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Interim Results of Russian Prospective Multicenter Trial RU-SKI

Prognostic Model of Successful Tyrosine Kinase Inhibitors Discontinuation Based on the Russian RU-SKI Multicenter Prospective Study

Analysis of the Effectiveness of Maintenance Therapy By Imatinib in Patients with Pdgfra -Positive Neoplasm

Long-Term Results and Characteristics of Pleural Effusion in Late Chronic Phase Chronic Myeloid Leukemia Patients at Dasatinib Therapy after Imatinib Failure

Alterations in the Physiology of Multipotent Mesenchymal Stromal Cells from the Bone Marrow of Patients with Leukemia

Pharmacoeconomical Analysis of Chronic Myelogenous Leukemia Treatment Free Remission

Polymorphism of UGT1A1 and Frequency of Hyperbilirubinemia in Patients with Chronic Myeloid Leukemia Treated By Nilotinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only